Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer

被引：1

作者：

Bolla, M. ^{[1
]}

Fourneret, P. ^{[1
]}

Descotes, J. -L. ^{[2
]}

机构：

[1] CHU, Clin Univ Cancerol Radiotherapie, F-63011 Grenoble, France

[2] CHU, Clin Univ Urol, F-63011 Grenoble, France

来源：

BULLETIN DU CANCER | 2008年 / 95卷 / 12期

关键词：

high-risk prostate cancer; combination of external irradiation and androgen suppression;

D O I：

10.1684/bdc.2008.0755

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment of high-risk prostate cancer-localized or locally advanced-is based on the combination of external irradiation and hormonal treatment by LHRH analogue (aLHRH) according to the results of phases III randomized trials RTOG and/or EORTC trials. These trials show a significant improvement of overall or specific survival. Localized prostate cancer require 6-month complete androgen blockade, while locally advanced prostate cancer need a long-term hormonal treatment for a duration ranging from 2,5 to 3 years. Some trials, which have a long follow-up show that the risk of cardiovascular death is not significantly increased by hormonal treatment.

引用

页码：1213 / 1218

页数：6

共 50 条

[31] CALCIFICATION AND IMAGE GUIDED RADIOTHERAPY FOR LOCALIZED HIGH-RISK PROSTATE CANCER
Faria, Sergio
Cuclos, Marie
Cury, Fabio
Patrocinio, Horacio
Souhami, Luis
RADIOTHERAPY AND ONCOLOGY, 2022, 174 : S65 - S65
[32] Current controversies in the treatment of high-risk prostate cancer
Mitchell, Robert E.
Chang, Sam S.
CURRENT OPINION IN UROLOGY, 2008, 18 (03) : 263 - 268
[33] Optimal Treatment for High-Risk Prostate Cancer Reply
Kishan, Atnar U.
Cook, Ryan R.
King, Christopher R.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (04): : 405 - 405
[34] Hypofractionated radiotherapy in high-risk prostate cancer using helical tomotherapy
Pervez, N.
Pearcey, R.
Parliament, M.
Yee, D.
Amanie, J.
Murtha, A.
Pederson, J.
Mihai, A.
Mackenzie, M.
Wachowicz, K.
Fallone, G.
RADIOTHERAPY AND ONCOLOGY, 2007, 84 : S94 - S94
[35] Adjuvant Versus Salvage Radiotherapy for High-Risk Prostate Cancer Patients
King, Christopher R.
SEMINARS IN RADIATION ONCOLOGY, 2013, 23 (03) : 215 - 221
[36] Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review
Foerster, Robert
Zwahlen, Daniel Rudolf
Buchali, Andre
Tang, Hongjian
Schroeder, Christina
Windisch, Paul
Vu, Erwin
Akbaba, Sati
Bostel, Tilman
Sprave, Tanja
Zamboglou, Constantinos
Zilli, Thomas
Stelmes, Jean-Jacques
Telkhade, Tejshri
Murthy, Vedang
CANCERS, 2021, 13 (04) : 1 - 17
[37] High-risk Prostate Cancer: Adjuvant versus early Salvage Radiotherapy
Lorenz, Judith
AKTUELLE UROLOGIE, 2022, 53 (01) : 13 - 13
[38] DOSIMETRIC STUDY OF PELVIC PROTON RADIOTHERAPY FOR HIGH-RISK PROSTATE CANCER
Chera, Bhishamjit S.
Vargas, Carlos
Morris, Christopher G.
Louis, Debbie
Flampouri, Stella
Yeung, Daniel
Duvvuri, Srividya
Li, Zuofeng
Mendenhall, Nancy Price
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (04): : 994 - 1002
[39] The Association between Dose Escalation and Risk of Developing Metastases in Intermediate and High-Risk Prostate Cancer Patients Treated with Radiotherapy
Miszczyk, M.
Magrowski, L.
Ciepal, J.
Stando, R.
Masri, O.
Jablonska, I.
Stawiski, K.
Krzysztofiak, T.
Wojcieszek, P.
Depowska, G.
Chimiak, K.
Bylica, G.
Gmerek, M.
Rajwa, P.
Suwinski, R.
Sadowski, J.
Rembak-Szynkiewicz, J.
Majewski, W.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E231 - E231
[40] Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment
Reichard, Chad A.
Hoffman, Karen E.
Tang, Chad
Williams, Stephen B.
Allen, Pamela K.
Achim, Mary F.
Kuban, Deborah A.
Chapin, Brian F.
BJU INTERNATIONAL, 2019, 124 (05) : 811 - 819

← 1 2 3 4 5 →